CA2958949A1 - Vaccine compositions against dengue virus diseases - Google Patents
Vaccine compositions against dengue virus diseases Download PDFInfo
- Publication number
- CA2958949A1 CA2958949A1 CA2958949A CA2958949A CA2958949A1 CA 2958949 A1 CA2958949 A1 CA 2958949A1 CA 2958949 A CA2958949 A CA 2958949A CA 2958949 A CA2958949 A CA 2958949A CA 2958949 A1 CA2958949 A1 CA 2958949A1
- Authority
- CA
- Canada
- Prior art keywords
- dengue
- serotype
- composition
- virus
- dengue virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000725619 Dengue virus Species 0.000 title claims abstract description 229
- 229960005486 vaccine Drugs 0.000 title claims abstract description 222
- 239000000203 mixture Substances 0.000 title claims abstract description 156
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 25
- 201000010099 disease Diseases 0.000 title description 8
- 208000025729 dengue disease Diseases 0.000 claims abstract description 391
- 206010012310 Dengue fever Diseases 0.000 claims abstract description 330
- 208000001490 Dengue Diseases 0.000 claims abstract description 286
- 230000002238 attenuated effect Effects 0.000 claims abstract description 83
- 239000000427 antigen Substances 0.000 claims abstract description 63
- 108091007433 antigens Proteins 0.000 claims abstract description 63
- 102000036639 antigens Human genes 0.000 claims abstract description 63
- 241000710831 Flavivirus Species 0.000 claims abstract description 21
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 59
- 208000003152 Yellow Fever Diseases 0.000 claims description 54
- 208000009714 Severe Dengue Diseases 0.000 claims description 45
- 230000009467 reduction Effects 0.000 claims description 30
- 230000002265 prevention Effects 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 241000710772 Yellow fever virus Species 0.000 claims description 5
- 229940051021 yellow-fever virus Drugs 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 14
- 239000012528 membrane Substances 0.000 abstract description 3
- 239000012071 phase Substances 0.000 description 88
- 241000700605 Viruses Species 0.000 description 34
- 239000002773 nucleotide Substances 0.000 description 34
- 125000003729 nucleotide group Chemical group 0.000 description 34
- 238000004458 analytical method Methods 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 241000710829 Dengue virus group Species 0.000 description 18
- 206010037660 Pyrexia Diseases 0.000 description 17
- 238000010240 RT-PCR analysis Methods 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 230000005847 immunogenicity Effects 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 230000007774 longterm Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 230000003472 neutralizing effect Effects 0.000 description 11
- 210000003501 vero cell Anatomy 0.000 description 10
- 101710204837 Envelope small membrane protein Proteins 0.000 description 9
- 101710145006 Lysis protein Proteins 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 208000001953 Hypotension Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 201000009892 dengue shock syndrome Diseases 0.000 description 5
- 238000005534 hematocrit Methods 0.000 description 5
- 230000002008 hemorrhagic effect Effects 0.000 description 5
- 230000036543 hypotension Effects 0.000 description 5
- 230000008520 organization Effects 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108091092724 Noncoding DNA Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000003443 Unconsciousness Diseases 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010043554 thrombocytopenia Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101100169272 Escherichia coli (strain K12) cydB gene Proteins 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 238000007476 Maximum Likelihood Methods 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 101100450407 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HEM1 gene Proteins 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 206010058874 Viraemia Diseases 0.000 description 3
- 239000004295 calcium sulphite Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 238000011976 chest X-ray Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000004293 potassium hydrogen sulphite Substances 0.000 description 3
- 230000035485 pulse pressure Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000710815 Dengue virus 2 Species 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 208000002091 Febrile Seizures Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000003623 Hypoalbuminemia Diseases 0.000 description 2
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 2
- 238000012351 Integrated analysis Methods 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 229940124928 YF-Vax Drugs 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 206010016284 febrile convulsion Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000002887 multiple sequence alignment Methods 0.000 description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 208000008494 pericarditis Diseases 0.000 description 2
- 238000009522 phase III clinical trial Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 206010040560 shock Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- IUORPUMMDWHUDA-WCCKRBBISA-N (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid hypochlorous acid Chemical compound ClO.OC(=O)[C@@H](N)CCCNC(N)=N IUORPUMMDWHUDA-WCCKRBBISA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- QHQZEEGNGSZBOL-UHFFFAOYSA-N 2-(aminomethyl)-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(CO)(CO)CO QHQZEEGNGSZBOL-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000097 Abdominal tenderness Diseases 0.000 description 1
- 208000011841 Abnormal homeostasis Diseases 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000337007 Oceania Species 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012072 active phase Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000004303 calcium sorbate Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000021821 cold clammy skin Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002856 computational phylogenetic analysis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000002873 global sequence alignment Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 208000011759 gum bleeding Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000011240 pooled analysis Methods 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012066 statistical methodology Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000037972 tropical disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306350 | 2014-09-02 | ||
| EP14306350.1 | 2014-09-02 | ||
| EP15305851.6 | 2015-06-04 | ||
| EP15305851 | 2015-06-04 | ||
| PCT/EP2015/070060 WO2016034629A1 (en) | 2014-09-02 | 2015-09-02 | Vaccine compositions against dengue virus diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2958949A1 true CA2958949A1 (en) | 2016-03-10 |
Family
ID=54064325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2958949A Pending CA2958949A1 (en) | 2014-09-02 | 2015-09-02 | Vaccine compositions against dengue virus diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10946087B2 (OSRAM) |
| EP (1) | EP3188751A1 (OSRAM) |
| JP (1) | JP2017526689A (OSRAM) |
| KR (2) | KR20170043660A (OSRAM) |
| CN (1) | CN106999564A (OSRAM) |
| AU (1) | AU2015310951A1 (OSRAM) |
| BR (1) | BR112017004197A2 (OSRAM) |
| CA (1) | CA2958949A1 (OSRAM) |
| MX (1) | MX2017002794A (OSRAM) |
| MY (1) | MY192739A (OSRAM) |
| PH (1) | PH12017500304A1 (OSRAM) |
| SG (1) | SG11201701256RA (OSRAM) |
| TW (1) | TWI852899B (OSRAM) |
| WO (1) | WO2016034629A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2933970T3 (es) | 2013-03-15 | 2023-02-15 | Takeda Vaccines Inc | Composiciones y métodos para construcciones quiméricas de virus del dengue en vacunas |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| CA3020484A1 (en) | 2016-04-13 | 2017-10-19 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
| US11531029B2 (en) | 2017-05-08 | 2022-12-20 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods and compositions for the detection of flavivirus infections |
| SG11202002933TA (en) | 2017-10-05 | 2020-04-29 | Sanofi Pasteur | Compositions for booster vaccination against dengu |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| CA3111332A1 (en) | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| AU2020331884B2 (en) | 2019-08-16 | 2025-01-23 | Takeda Vaccines, Inc. | Methods for preventing dengue and Hepatitis A |
| WO2025072259A1 (en) | 2023-09-25 | 2025-04-03 | Takeda Vaccines, Inc. | Coadministration of tetravalent dengue vaccine with hpv vaccine |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2741077B1 (fr) * | 1995-11-14 | 1998-01-23 | Pasteur Institut | Vaccin polyvalent anti-dengue |
| US6962708B1 (en) | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| KR100517323B1 (ko) | 1997-02-28 | 2005-09-27 | 아캠비스 인코포레이티드 | 키메라 플라비바이러스 백신 |
| US7227011B2 (en) | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| AU1813901A (en) | 1999-12-01 | 2001-06-12 | Oravax, Inc | Chimeric flavivirus vaccines |
| DK2278012T3 (en) | 2000-02-16 | 2015-12-07 | Us Government | Immunogenic dengue 2 virus chimeras |
| JP2005501532A (ja) | 2001-06-01 | 2005-01-20 | アカンビス インコーポレーティッド | キメラフラビウイルスベクター |
| KR101194818B1 (ko) | 2002-01-15 | 2012-10-25 | 사노피 파스테르 바이오로직스, 엘엘씨 | 플라비바이러스 백신 |
| US20050002968A1 (en) | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
| AU2003239932A1 (en) | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| KR101536612B1 (ko) | 2005-06-17 | 2015-07-14 | 사노피 파스퇴르 | 약독화된 뎅기 혈청형 1 균주 |
| MX2007015872A (es) | 2005-06-17 | 2008-04-21 | Sanofi Pasteur | Cepa atenuada del serotipo 2 del dengue. |
| KR101357685B1 (ko) | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
| CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| US7968102B2 (en) | 2006-01-13 | 2011-06-28 | Sanofi Pasteur S.A. | Dengue chimeric viruses |
| FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| WO2008115314A2 (en) | 2007-01-31 | 2008-09-25 | Sanofi Pasteur Biologics Co. | Flavivirus vaccine vector against influenza virus |
| WO2009134717A1 (en) | 2008-04-30 | 2009-11-05 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Chimeric west nile/dengue viruses |
| EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| US8968996B2 (en) * | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| CN106421743A (zh) | 2009-07-29 | 2017-02-22 | 贝恩德·赫尔穆特·阿达姆·雷姆 | 聚合物微粒及其用途 |
| EP2353609A1 (en) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
| MX2012012681A (es) * | 2010-05-21 | 2012-12-17 | Univ Pittsburgh | Secuencias del virus de dengue universales y metodos de uso. |
| WO2012051491A1 (en) | 2010-10-14 | 2012-04-19 | The United States Of America, As Represented By The Secretary National Institutes Of Health | Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting |
| ITMI20121231A1 (it) * | 2012-07-16 | 2014-01-17 | St Microelectronics Srl | Metodo di controllo burst-mode per basso consumo in ingresso in convertitori risonanti e relativo dispositivo di controllo |
| EP3932422A1 (en) | 2012-07-24 | 2022-01-05 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
| WO2014016362A1 (en) * | 2012-07-24 | 2014-01-30 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| WO2017005654A1 (en) * | 2015-07-03 | 2017-01-12 | Sanofi Pasteur | Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination. |
-
2015
- 2015-09-01 TW TW104128945A patent/TWI852899B/zh active
- 2015-09-02 US US15/507,952 patent/US10946087B2/en active Active
- 2015-09-02 MX MX2017002794A patent/MX2017002794A/es unknown
- 2015-09-02 SG SG11201701256RA patent/SG11201701256RA/en unknown
- 2015-09-02 KR KR1020177008402A patent/KR20170043660A/ko not_active Ceased
- 2015-09-02 MY MYPI2017700549A patent/MY192739A/en unknown
- 2015-09-02 KR KR1020237042016A patent/KR20230170812A/ko active Pending
- 2015-09-02 AU AU2015310951A patent/AU2015310951A1/en not_active Abandoned
- 2015-09-02 WO PCT/EP2015/070060 patent/WO2016034629A1/en not_active Ceased
- 2015-09-02 CN CN201580046426.3A patent/CN106999564A/zh active Pending
- 2015-09-02 CA CA2958949A patent/CA2958949A1/en active Pending
- 2015-09-02 JP JP2017511914A patent/JP2017526689A/ja active Pending
- 2015-09-02 EP EP15759746.9A patent/EP3188751A1/en not_active Withdrawn
- 2015-09-02 BR BR112017004197A patent/BR112017004197A2/pt not_active Application Discontinuation
-
2017
- 2017-02-17 PH PH12017500304A patent/PH12017500304A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015310951A1 (en) | 2017-03-16 |
| SG11201701256RA (en) | 2017-03-30 |
| EP3188751A1 (en) | 2017-07-12 |
| TWI852899B (zh) | 2024-08-21 |
| CN106999564A (zh) | 2017-08-01 |
| MY192739A (en) | 2022-09-06 |
| TW201620546A (zh) | 2016-06-16 |
| US20170304426A1 (en) | 2017-10-26 |
| KR20170043660A (ko) | 2017-04-21 |
| WO2016034629A1 (en) | 2016-03-10 |
| KR20230170812A (ko) | 2023-12-19 |
| US10946087B2 (en) | 2021-03-16 |
| MX2017002794A (es) | 2017-06-14 |
| PH12017500304A1 (en) | 2017-07-10 |
| BR112017004197A2 (pt) | 2017-12-12 |
| JP2017526689A (ja) | 2017-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10946087B2 (en) | Vaccine compositions against dengue virus diseases | |
| JP6830118B2 (ja) | ワクチン組成物 | |
| US20150265695A1 (en) | Vaccine compositions for prevention against dengue virus infection | |
| Thomas et al. | Vaccines for the prevention of dengue: development update | |
| US20230338504A1 (en) | Compositions for Booster Vaccination Against Dengue | |
| WO2014083194A1 (en) | Methods for inducing antibodies | |
| CA3147807A1 (en) | Methods for preventing dengue and hepatitis a | |
| CA2878682C (en) | Vaccine compositions for use in a method of protecting a human subject against dengue disease | |
| HK1242193A1 (en) | Vaccine compositions against dengue virus diseases | |
| HK1212906B (en) | Vaccine compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200901 |
|
| EEER | Examination request |
Effective date: 20200901 |
|
| EEER | Examination request |
Effective date: 20200901 |
|
| EEER | Examination request |
Effective date: 20200901 |
|
| EEER | Examination request |
Effective date: 20200901 |
|
| EEER | Examination request |
Effective date: 20200901 |
|
| EEER | Examination request |
Effective date: 20200901 |
|
| EEER | Examination request |
Effective date: 20200901 |